GC resistance in some cases of ALL is determined by the hypermethylation in lymphocyte-specific open regions of DNA, resulting in a decreased accessibility and a prevention of the correct docking of GC-GR complexes with target genes as the pro-apoptotic BIM [(48), discussed in Effects of GCs on Sensitive Lymphocytes)]. The gene discussed is NR3C1; the disease is acute lymphoblastic leukemia.